Suggestions
Dan Karlin
Chief Medical Officer at MindMed (MNMD) | Improving psychiatry, healthcare, and health-tech from clinical development to the bedside
Dr. Daniel Rollings Karlin, MD, MA is a prominent figure in the fields of psychiatry, addiction medicine, and clinical informatics. He currently serves as the Chief Medical Officer at MindMed, a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders.12 Dr. Karlin joined MindMed in February 2021 following the company's acquisition of HealthMode, which he co-founded and led as CEO.2
Dr. Karlin has been a member of the Board of Directors at Sonara Health since October 2022.3 Sonara Health is a company that helps patients earn take-home methadone earlier by building patient-provider trust and guiding patients through their recovery journey.3
In addition to his roles at MindMed and Sonara Health, Dr. Karlin holds several other positions:
- Assistant Professor at Tufts University School of Medicine since July 20133
- Chief Scientific Advisor at NightWare, a company developing digital therapeutics for nightmares related to PTSD3
- Senior Advisor at Recovery Delivered, which provides Medication Assisted Treatment for addiction3
- Medical Advisor at Limitless Ventures, an impact capital firm investing in mental health and substance use disorder solutions3
Dr. Karlin is board certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is a Fellow of the American Psychiatric Association and the American Society of Addiction Medicine.1 His educational background includes degrees in Neuroscience and Behavior (BA) and Clinical Informatics (MA) from Columbia University, and a Doctor of Medicine (MD) from the University of Colorado School of Medicine.13
Throughout his career, Dr. Karlin has held leadership positions in various healthcare and pharmaceutical organizations, including Pfizer, where he led clinical, informatics, and regulatory strategy for digital medicine initiatives.3 His expertise spans across psychiatry, addiction treatment, medical informatics, and drug development, making him a valuable asset to the companies and institutions he serves.
Highlights




